Physician
Revival Pain Management INC
Revival Pain Management INC was paid $744K by Medicaid between Oct 2021 and Dec 2024, across 29 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 50% of everything it billed.
33Billing provider infoREVIVAL PAIN MANAGEMENT INC
ELKIN, NC 28621
ELKIN, NC 28621
33aNPI1801813712assigned 07/16/2006
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$744K
24GClaims26,817
24DCodes billed29
24AFirst – last monthOct 2021 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in North Carolina
Rank by total paid#10 of 43
Median peer was paid$90K
This provider vs. median8.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 2,481 | $33K | |
| 2022 | 8,964 | $232K | |
| 2023 | 8,596 | $249K | |
| 2024incomplete | 6,776 | $231K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 50% | 11,872 | 8,328 | $372K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 17% | 3,979 | 2,984 | $129K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 13% | 2,075 | 1,494 | $99K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.0% | 3,383 | 2,376 | $67K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 7.6% | 1,370 | 1,110 | $56K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.5% | 102 | 96 | $11K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 33 | 26 | $3K |
| 96127 | <1% | 840 | 652 | $2K | |
| 80305 | <1% | 475 | 297 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 586 | 430 | $1K |
| 72100 | <1% | 128 | 98 | $998.08 | |
| 64493 | <1% | 18 | 15 | $620.96 |
17 more codes
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 203 | $614.34 |
| 64494 | <1% | 18 | $301.78 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $210.85 |
| 99406 | <1% | 52 | $181.01 | |
| 1123F | <1% | 360 | $0.01 | |
| 1100F | 0% | 367 | $0.00 | |
| 0518F | 0% | 32 | $0.00 | |
| G9900 | Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified | 0% | 13 | $0.00 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 177 | $0.00 |
| G8400 | Patient with central dual-energy x-ray absorptiometry (dxa) results not documented, reason not given | 0% | 16 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 14 | $0.00 |
| G8432 | Depression screening not documented, reason not given | 0% | 192 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 116 | $0.00 |
| 3017F | 0% | 204 | $0.00 | |
| 1036F | 0% | 63 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 16 | $0.00 |
| G9716 | Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason | 0% | 99 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNOVEMBRE, EMIDIO (PRACTICE OWNER)